# A Phase I Study of YK012 in Primary Membranous Nephropathy

> **NCT07234474** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Excyte Biopharma Ltd** · enrollment: 66 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** YK012

## Key facts

- **NCT ID:** NCT07234474
- **Lead sponsor:** Excyte Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234474, "A Phase I Study of YK012 in Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07234474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*